Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $47 at Goldman Sachs
Tweet
Share
E-mailGet Alerts AMLX Hot Sheet
Price: $29.28 -1.91%
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 42
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 42
Join SI Premium – FREE
Goldman Sachs analyst Chris Shibutani raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $47.00 (from $41.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Dell (DELL) PT Raised to $550 at TD Cowen
- Generac Holdings (GNRC) PT Lowered to $279 at Jefferies
- Iovanace Biotherapeutics (IOVA) PT Raised to $16 at TD Cowen Following Raised Outlook
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
